Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EUDA Health Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EUDA Health Holdings's regulatory disclosures and financial reporting.
EUDA Health Holdings Limited filed a 424(b)(5) prospectus supplement dated 23 June 2025 that activates an at-the-market (ATM) share offering of up to $10.0 million of ordinary shares under its October 2024 F-3 shelf (total capacity $100 million). Chardan Capital Markets will act as sales agent, earning 3% of gross proceeds on ordinary market sales and 7% on block transactions; the firm will be deemed an underwriter and receives customary indemnification. Shares will be sold from time to time at prevailing market prices (last close 20 June 2025: $3.72).
The filing reiterates recent strategic actions:
- Discontinued Operations (Sept 2023) – closure of medical clinics to curb losses, leaving property-management services as the principal operating segment.
- CK Health Acquisition (May 2024) – purchase completed for $15.0 million in stock (8.57 million shares at $1.75) plus up to 1 million contingent shares; CK Health contributed ~2.1% of FY 2024 revenue.
- Stem-cell Collaboration (Apr 2025) – CK Health to market Guangdong Cell Biotech’s therapies in Singapore and Malaysia under a terminable agreement with Key Lock.
As required, the supplement directs investors to the Risk Factors section (page S-4) and reminds readers that ATM proceeds, dilution impact, and the company’s evolving business model require careful consideration.
FAQ
What is the current stock price of EUDA Health Holdings (EUDAW)?
